



IFW

**TRANSMITTAL
FORM***(To be used for all correspondence
after initial filing)*

Application Number	10/775,972
Filing Date	February 10, 2004
First Named Inventor	Robert A. Henderson
Art Unit	1645
Examiner Name	
Attorney Docket No.	210121.455C21

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> After Allowance Communication to Technology Center (TC)
<input type="checkbox"/> Amendment/Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (<i>Appeal Notice, Brief, Reply Brief</i>)
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 (13 Sheets)	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	<input type="checkbox"/> Additional Enclosure(s) (<i>please identify below</i>):
<input type="checkbox"/> Cited References	<input type="checkbox"/> Terminal Disclaimer	_____
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	_____
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53		_____
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		_____

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Julie A. Urvater, Ph.D., Patent Agent Reg. No. 50,461	Customer Number 00500
Signature		
Date	September 7, 2004	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Lawrence Teague	
Signature		Date: September 7, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

513272

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



September 7, 2004
Date

Lawrence Teague
Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Robert A. Henderson et al.
Application No. : 10/775,972
Filed : February 10, 2004
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF LUNG CANCER

Art Unit : 1645
Docket No. : 210121.455C21
Date : September 7, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 10/623,155, filed July 17, 2003; which is a continuation-in-part of USAN 10/313,986, filed December 4, 2002; which is a continuation-in-part of USAN 10/117,982, filed April 5, 2002; which is a continuation-in-part of USAN 10/007,700, filed November 30, 2001; which is a continuation-in-part of USAN 09/897,778, filed June 28, 2001; which is a continuation-in-part of USAN 09/850,716, filed May 7, 2001; which is a continuation-in-part of USAN 09/735,705, filed December 12, 2000; which is a continuation-in-part of USAN 09/685,696, filed October 9, 2000; which is a continuation-in-part of USAN 09/662,786, filed September 15, 2000; which is a continuation-in-part of USAN 09/643,597, filed August 21, 2000; which is a continuation-in-part of USAN 09/630,940, filed August 2, 2000; which is a continuation-in-part of USAN 09/606,421, filed June 28, 2000; which

is a continuation-in-part of USAN 09/542,615, filed April 4, 2000; which is a continuation-in-part of USAN 09/510,376, filed February 22, 2000; which is a continuation-in-part of USAN 09/480,884, filed January 10, 2000; which is a continuation-in-part of USAN 09/476,496, filed December 30, 1999; which is a continuation-in-part of USAN 09/466,396, filed December 17, 1999; which is a continuation-in-part of USAN 09/285,479, filed April 2, 1999; which is a continuation-in-part of USAN 09/221,107, filed December 22, 1998; which is a continuation-in-part of USAN 09/123,912, filed July 27, 1998; which is a continuation-in-part of USAN 09/040,802, filed March 18, 1998. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Office in these prior applications and, therefore, are not required to be provided in the present application. If the Examiner wishes, copies will be provided upon request.


As to any reference made of record on the attached Form PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC


Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

JAU:ljt

Enclosures:

Postcard

Form PTO-1449 (13 Sheets)

701 Fifth Avenue, Suite 6300

Seattle, Washington 98104-7092

Phone: (206) 622-4900

Fax: (206) 682-6031

513278

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.455C21APPLICATION NO.
10/775,972

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Robert A. Henderson et al.

FILING DATE

February 10, 2004

GROUP ART UNIT

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,589,579	12/31/96	Torczynski et al.	536	23.1	
	AB	5,705,159	01/06/98	Irie et al	424	185.1	
	AC	5,783,422	07/21/98	Suminami et al.	435	69.3	
	AD	6,200,764	03/13/00	Carney	435	7.23	
	AE	6,297,364	10/2/01	Chen et al.	536	23.1	
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	EP 1033401 A2	09/06/00	EPO		
	AL	EP 1130094 A2	09/05/01	EPO		
	AM	EP 679716 A1	11/11/94	EPO		
	AN	EP 695760 A1	02/07/96	EPO		
	AO	WO 91/18926	12/12/91	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Ackermann, R. "Monoclonal antibodies," <i>Human Cell</i> 1(1): 46-53, 1988 (Abstract Only; PubMed ID:3154013).
	AQ	Arceci, R.J., "The potential for antitumor vaccination in acute myelogenous leukemia," <i>J. Mol. Med.</i> 76: 80-93, 1998.
	AR	Baldi et al., "Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer," <i>Clinical Cancer Research</i> 3(10):1691-1697, October 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.455C21	APPLICATION NO. 10/775,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Robert A. Henderson et al.	
		FILING DATE February 10, 2004	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BB	WO 94/06929	03/31/94	WIPO		
	BC	WO 95/21862	08/17/95	WIPO		
	BD	WO 96/02552	02/01/96	WIPO		
	BE	WO 96/28473	09/19/96	WIPO		
	BF	WO 96/30389	10/03/96	WIPO		
	BG	WO 97/07244	02/27/97	WIPO		
	BH	WO 98/35985	08/20/98	WIPO		
	BI	WO 98/46788	10/22/98	WIPO		
	BJ	WO 99/38973	08/05/99	WIPO		
	BK	WO 99/46594	09/16/99	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BL	Bergers and Coussens, "Extrinsic regulators of epithelial tumor progression: metalloproteinases," <i>Current Opinion in Genetics & Developments</i> 10: 120-127, 200.
	BM	Bodey, B. et al., "Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy," <i>Anticancer Research</i> 20: 2665-2676, 2000.
	BN	Boon, T., "Toward a Genetic Analysis of Tumor Rejection Antigens," <i>Advances in Cancer Research</i> 58: 177-210, 1992.
	BO	Brass et al., "Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma," <i>Human Molecular Genetics</i> , 6(1): 33-39, 1997.
	BP	Chen, Shen-Lin et al., "Isolation and characterization of a novel gene expressed in multiple cancers," <i>Oncogene</i> 12: 741-751, 1996.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.455C21

APPLICATION NO.

10/775,972

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Robert A. Henderson et al.

FILING DATE

February 10, 2004

GROUP ART UNIT

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CB	WO 99/47674	09/23/99	WIPO		
	CC	WO 99/54738	10/28/99	WIPO		
	CD	WO 00/61612	10/19/00	WIPO		
	CE	WO 01/47944	07/05/01	WIPO		
	CF	WO 01/55322	08/02/01	WIPO		
	CG	WO 01/57272	08/09/01	WIPO		
	CH	WO 01/57275	08/09/01	WIPO		
	CI	WO 01/57276	08/09/01	WIPO		
	CJ	WO 01/57277	08/09/01	WIPO		
	CK	WO 01/75067	10/11/01	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CL	Chen, Y.-T. et al., "A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening" <i>Proc. Natl. Acad. Sci. USA</i> 94: 1914-1918, March 1997.
	CM	Database EMBL Nucleotide and Protein Sequence, Accession No. AI468638, March 17, 1999.
	CN	Database EMBLest17 Accession No. AA340797:EST46165 Fetal kidney II Homo sapiens cDNA 3' end, April 18, 1997.
	CO	Database EMBLest17 Accession No. W22264:Human retina cDNATsp-509I-cleaved sublibrary Homo sapiens cDNA not directional, May 9, 1996.
	CP	Davidson et al., "Lung tumours immunoreactive for parathyroid hormone related peptide: analysis of serum calcium levels and tumour type," <i>Journal of Pathology</i> 178:398-401, January 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.455C21	APPLICATION NO. 10/775,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Robert A. Henderson et al.	
		FILING DATE February 10, 2004	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	DB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	DC	Eck and Wilson, "Gene-Based Therapy," in <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , 9 th Edition, McGraw-Hill, New York, 1996, pgs. 77-101.
	DD	Ezzell, C., "Cancer 'Vaccines': An Idea Whose Time Has Come?" <i>The Journal of NIH Research</i> 7: 46-49, January 1995.
	DE	Finch et al., "Identification of a cloned sequence activated during multi-stage carcinogenesis in mouse skin," <i>Carcinogenesis</i> , 12(8):1519-1522, August 1991.
	DF	GenBank Database, Accession No. AAB82295, October 30, 1997.
	DG	GenBank Database, Accession No. AAB97457, January 22, 1998.
	DH	GenBank Database, Accession No. AAC18597, June 3, 1998.
	DI	GenBank Database, Accession No. AAC18598, June 3, 1998.
	DJ	GenBank Database, Accession No. AAC35208, May 13, 1997.
	DK	GenBank Database, Accession No. AAC41285, May 13, 1998.
	DL	GenBank Database, Accession No. AAD09223, January 26, 1999.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.455C21

APPLICATION NO.

10/775,972

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Robert A. Henderson et al.

FILING DATE

February 10, 2004

GROUP ART UNIT

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	EB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	EC		GenBank Database, Accession No. AAD09827, January 26, 1999.
	ED		GenBank Database, Accession No. AAD09828, January 26, 1999.
	EE		GenBank Database, Accession No. AAF37203, March 2, 2000.
	EF		GenBank Database, Accession No. AC005082, September 8, 1999.
	EG		GenBank Database, Accession No. AC021876, January 21, 2000.
	EH		GenBank Database, Accession No. AC079780, February 21, 2002.
	EI		GenBank Database, Accession No. AC092447, July 4, 2001.
	EJ		GenBank Database, Accession No. AF043977, June 23, 1999.
	EK		GenBank Database, Accession No. AF117108, January 26, 1999.
	EL		GenBank Database, Accession No. AF198254, March 2, 2000.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.455C21	APPLICATION NO. 10/775,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Robert A. Henderson et al.	
		FILING DATE February 10, 2004	GROUP ART UNIT 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
FB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

FC	GenBank Database, Accession No. AL023775, November 23, 1999.
FD	GenBank Database, Accession No. BAB19755, December 20, 2000.
FE	GenBank Database, Accession No. BAB27779, February 8, 2001.
FF	GenBank Database, Accession No. BAB27848, February 8, 2001.
FG	GenBank Database, Accession No. BC019258, December 19, 2001.
FH	GenBank Database, Accession No. NM_006547, November 1, 2000.
FI	GenBank Database, Accession No. NP_006537, August 10, 1999.
FJ	GenBank Database, Accession No. NP_006538, November 1, 2000.
FK	GenBank Database, Accession No. NP_006539, August 10, 1999.
FL	GenBank Database, Accession No. NP_034081, January 25, 2000.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.455C21APPLICATION NO.
10/775,972**INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

APPLICANTS

Robert A. Henderson et al.

FILING DATE

February 10, 2004

GROUP ART UNIT

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	GB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	GC	GenBank Database, Accession No. NP_076159, February 19, 2001.
	GD	GenBank Database, Accession No. NP_571566, February 20, 2002.
	GE	GenBank Database, Accession No. O00425, July 1, 1997.
	GF	GenBank Database, Accession No. U76705, January 26, 1999.
	GG	GenBank Database, Accession No. U85946, July 30, 1999.
	GH	GenBank Database, Accession No. U97188, May 20, 1997.
	GI	GenBank Database, Accession No. XM_004780, November 16, 2000.
	GJ	GenBank Database, Accession No. XP_004780, November 16, 2000.
	GK	Geneseq Accession Number AAC66035, February 21, 2001.
	GL	Geneseq Accession Number AAZ24653, December 7, 1999.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.455C21APPLICATION NO.
10/775,972**INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

APPLICANTS

Robert A. Henderson et al.

FILING DATE

February 10, 2004

GROUP ART UNIT

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	HB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	HC	Geneseq Accession Number AAZ36150, December 7, 1999.
	HD	Geneseq Database (Thomson Derwent), Accession AAL28189, January 24, 2002.
	HE	Geneseq Database (Thomson Derwent), Accession AAL28189, January 24, 2002.
	HF	Geneseq Database (Thomson Derwent), Accession AAM93826, November 6, 2001.
	HG	Geneseq Database (Thomson Derwent), Accession AAM93826, November 6, 2001.
	HH	Geneseq Database (Thomson Derwent), Accession AAT26750, October 23, 1996.
	HI	Geneseq Database (Thomson Derwent), Accession AAT26750, October 23, 1996.
	HJ	Geneseq Database (Thomson Derwent), Accession AAU16161, November 7, 2001.
	HK	Geneseq Database (Thomson Derwent), Accession AAU16161, November 7, 2001.
	HL	Geneseq Database (Thomson Derwent), Accession AAU16163, November 7, 2001.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.455C21

APPLICATION NO.

10/775,972

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Robert A. Henderson et al.

FILING DATE

February 10, 2004

GROUP ART UNIT

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	IA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	IB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	IC		Geneseq Database (Thomson Derwent), Accession AAU16163, November 7, 2001.			
	ID		Geneseq Database (Thomson Derwent), Accession AAU16164, November 7, 2001.			
	IE		Geneseq Database (Thomson Derwent), Accession AAU16164, November 7, 2001.			
	IF		Geneseq Database (Thomson Derwent), Accession AAU16166, November 7, 2001.			
	IG		Geneseq Database (Thomson Derwent), Accession AAU16166, November 7, 2001.			
	IH		Geneseq Database (Thomson Derwent), Accession AAU16579, November 7, 2001.			
	II		Geneseq Database (Thomson Derwent), Accession AAU16579, November 7, 2001.			
	IJ		Geneseq Database (Thomson Derwent), Accession AAU16583, November 7, 2001.			
	IK		Geneseq Database (Thomson Derwent), Accession AAU16583, November 7, 2001.			
	IL		Gerhold and Caskey, "It's the genes! EST access to human genome content," <i>BioEssays</i> 18(12):973-981, 1996.			

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.455C21

APPLICATION NO.

10/775,972

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Robert A. Henderson et al.

FILING DATE

February 10, 2004

GROUP ART UNIT

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	JA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	JB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	JC	Greenspan and Cooper, "Complementarity, specificity and the nature of epitopes and paratopes in multivalent interactions," <i>Immunology Today</i> 16(5): 226-230, 1995.
	JD	Gruber et al., "Molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland," <i>Am. J. Physiol.</i> 276(Cell Physiol 45):C1261-C1270, 1999.
	JE	Guo et al., "Identification and characterization of homologues of the Exocyst component Sec10p," <i>FEBS Letters</i> 404(2-3):135-139, 1997.
	JF	Gura, T., "System for Identifying New Drugs Are Often Faulty," <i>Science</i> 278: 1041-1042, November 7, 1997.
	JG	Güre, A.O. et al., "Human Lung Cancer Antigens Recognized by Autologous Antibodies: Definition of a Novel cDNA Derived from the Tumor Suppressor," <i>Cancer Research</i> 58: 1034-1041, March 1, 1998.
	JH	Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8 α in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.
	JI	Henderson et al., "Identification of lung tumor antigens for cancer immunotherapy: immunological and molecular approaches," <i>Immunological Investigation</i> 29(2):87-91, May 2000.
	JJ	Hogan et al., "The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene," <i>Cancer Research</i> 58(22):5144-5150, November 15, 1998.
	JK	Hu et al., "A small proline-rich protein, spr1: specific marker for squamous lung carcinoma," <i>Lung Cancer</i> 20:25-30, 1998.
	JL	Jolly, D., "Viral vector systems for gene therapy," <i>Cancer Gene Therapy</i> 1(1):51-64, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.455C21		APPLICATION NO. 10/775,972	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Robert A. Henderson et al.			
				FILING DATE February 10, 2004		GROUP ART UNIT 1645	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	KA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	KB						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	KC	Kaye, F.J. et al. "A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding," <i>Proc. Natl. Acad. Sci. USA</i> 87: 6922-6926, September 1990.					
	KD	Lee, K-H. et al., "Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression," <i>The Journal of Immunology</i> 163: 6292-6300, 1999.					
	KE	Lelievre et al., "Structural properties of chimeric peptides containing a T-cell epitope linked to a fusion peptide and their importance for in vivo induction of cytotoxic T-cell responses," <i>European Journal of Biochemistry</i> 249(3):895-904, 1997.					
	KF	Marshall and Hodgson, "DNA chips: an array of possibilities," <i>Nature Biotechnology</i> 16:27-31, January 1998.					
	KG	Marusawa, H. et al., "HBXIP functions as a cofactor of surviving in apoptosis suppression," <i>EMBO Journal</i> 22(11): 2729-2740, 2003.					
	KH	Müller-Pillasch, F. et al., "Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein," <i>Oncogene</i> 14: 2729-2733, 1997.					
	KI	New England Biolabs website, Description on the pCyB Expression Vectors: http://circuit.neb.com/neb/faqs/impact2.html , (2001)					
	KJ	Nielsen, J. et al., "A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late Development," <i>Molecular and Cellular Biology</i> 19(2): 1262-1270, February 1999.					
	KK	Pastor et al., "Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis," <i>Eur. Respir J.</i> 10(3):603-609, March 1997.					
	KL	Radoja and Frey, "Cancer-induced Defective Cytotoxic T Lymphocyte Effector Function: Another Mechanism How Antigenic Tumors Escape Immune-mediated Killing," <i>Molecular Medicine</i> 6(6): 465-479, June 2000.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.455C21		APPLICATION NO. 10/775,972	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Robert A. Henderson et al.			
				FILING DATE February 10, 2004		GROUP ART UNIT 1645	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	LB						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	LC	Rammensee et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> 41:178-228, 1995.					
	LD	Ramsay, G., "DNA chips: state-of-the art," <i>Nature Biotechnology</i> 16:40-44, January 1998.					
	LE	Rudinger, J., "Characteristics of the amino acids as components of a peptide hormone sequence," in <i>Peptide Hormones</i> , Parsons, J.A. (ed.), University Park Press, Baltimore MD, June 1976, pgs. 1-7					
	LF	Ruppert et al., "Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules," <i>Cell</i> 74:929-937, September 10, 1993.					
	LG	Russell and Barton, "Structural features can be unconserved in proteins with similar folds," <i>J. Mol. Biol.</i> 244:332-350, 1994.					
	LH	Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258:815-818, October 30, 1992.					
	LI	Sjölander, A. et al., "Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins," <i>Vaccine</i> 15(9): 1030-1038, 1997.					
	LJ	Skeiky et al., "Cloning, expression and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis," <i>Infection and Immunity</i> 67(8):3998-4007, August 1999.					
	LK	Skolnick and Fetrow, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends in Biotechnology</i> 18: 34-39, January 2000.					
	LL	Spitler, L.E., "Cancer Vaccines: The Interferon Analogy," <i>Cancer Biotherapy</i> 10(1): 1-3, 1995.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.455C21	APPLICATION NO. 10/775,972	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Robert A. Henderson et al.		
				FILING DATE February 10, 2004		GROUP ART UNIT 1645
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MA						
FOREIGN PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
MB						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>						
*EXAMINER INITIAL	MC	Stern, P.S., "Predicting antigenic sites on proteins," <i>Trends in Biotechnology</i> 9: 163-169, May 1991.				
	MD	Theobald et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Acad. Sci. USA</i> 92:11993-11997, December 1995.				
	ME	Timmerman and Levy, "Dendritic Cell Vaccines for Cancer Immunotherapy," <i>Annu. Rev. Med.</i> 50: 507-529, 1999.				
	MF	Visseren et al., "Identification of HLA-A *0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product," <i>International Journal of Cancer</i> 73(1):125-130, 1997.				
	MG	Wang et al., "Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis," <i>Oncogene</i> 19(12):1519-1528, March 16, 2000.				
	MH	Wells and Peitsch, "The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and expressed sequence tag databases," <i>Journal of Leukocyte Biology</i> 61:545-550, May 1997.				
	MI	Wong, C.P. et al., "TCR Vaccines Against T Cell Lymphoma: QS-21 and IL-12 Adjuvants Induce a Protective CD8 ⁺ T Cell Response," <i>The Journal of Immunology</i> 162: 2251-2258, 1999.				
	MJ	Yee et al., "Isolation of tyrosinase-specific CD8 ⁺ and CD4 ⁺ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157:4079-4086, 1996.				
	MK	Zaks and Rosenberg, "Immunization with Peptide Epitope (p369-377) from HER-2/neu Leads to Peptide-specific Cytotoxic T Lymphocytes That Fail to Recognize HER-2/neu+ Tumors," <i>Cancer Research</i> 58: 4902-4908, November 1, 1998.				
EXAMINER				DATE CONSIDERED		
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).						